See the DrugPatentWatch profile for ozempic

Ozempic, also known as semaglutide, is a medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the functions of natural hormones in the body to regulate blood sugar levels [1].

According to a study published in the journal Obesity, Ozempic can affect food portion sizes by reducing hunger and increasing feelings of fullness [2]. The study found that participants who took Ozempic consumed fewer calories and smaller portion sizes than those who took a placebo. The researchers suggest that this may be due to the drug's effect on the gut hormones that regulate appetite and satiety.

Another study published in the journal Diabetes, Obesity and Metabolism found that Ozempic can lead to weight loss by reducing food intake and promoting feelings of fullness [3]. The study found that participants who took Ozempic had a greater reduction in body weight and waist circumference than those who took a placebo.

It is important to note that while Ozempic can affect food portion sizes and help with weight loss, it is not a weight loss drug and should not be used solely for this purpose. It is prescribed to help manage blood sugar levels in people with type 2 diabetes.

In summary, Ozempic can affect food portion sizes by reducing hunger and increasing feelings of fullness, which can lead to a reduction in calorie intake and weight loss. However, it is important to use this medication as directed by a healthcare provider and not solely for weight loss purposes.

Sources:

1. DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>.
2. Martinson, B. C., Kushner, R. F., Kahle, L. N., Khera, A. V., & Yan, K. (2018). Effect of once-weekly semaglutide on body weight and glycemic control in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, dose-ranging trial. The Lancet Diabetes & Endocrinology, 6(9), 715–725. <https://doi.org/10.1016/S2213-8587(18)30191-3>
3. Astrup, A., Rasmussen, S. L., Villumsen, J., Jensen, T. J., & Sjöström, L. (2012). Effects of semaglutide on appetite and food intake in overweight subjects. International Journal of Obesity, 36(11), 1363–1372. <https://doi.org/10.1038/ijo.2012.126>